The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

[2026 update] Reading a supplementary appendix and finding the interesting part

This is a generated summary. It shows the 6 most-liked posts from a topic of 45, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
G
GDashwoodTL3Regular7 Jan 2026#6
k.farrugia, post #1: On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Collecting what is known about Reading a supplementary appendix in one place, because it is currently spread across a category, two tag pages and a thread that is hard to find. This is a summary rather… Go to post

If someone has run Reading a supplementary appendix properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.

30 likes in reply to #1 7mo
CE
crossover_entryTL3Regular17 Jan 2026#13

Reading the supplementary appendix is where most of the real information is, and it is where almost nobody goes. The baseline table alone answers half the generalisability questions asked here.

25 likes 6mo
SS
s.salgadoTL231 Jan 2026#24
s.cardoso, post #9: I would call the community position on Reading a supplementary appendix likely rather than established, and I would be comfortable defending that hedge. Go to post

Where I part company with post #22, and it is a narrow parting.

A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened had everyone continued. Both are legitimate and they give different numbers.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

32 likes in reply to #9 6mo
F
FairweatherTL2Member4 Feb 2026#27

Practical answer on Reading a supplementary appendix, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.

23 likes 6mo
TL
t.lindqvistTL29 Feb 2026#32
gradient_review, post #11: Worth separating two things that post #8 runs together. Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment), concealment (could randomisation be subverted), blinding (who was blinded and why or why not), completeness of… Go to post

This follows post #29 rather than contradicting it.

I would rather this thread reach "we do not know" about Reading a supplementary appendix than reach a confident answer that nobody can support when asked.

30 likes in reply to #11 6mo
KS
k.salinasTL217 Feb 2026#39
br.wikstrom, post #14: Taking Reading a supplementary appendix seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences. Go to post

I disagree with the framing of Reading a supplementary appendix above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.

The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.

31 likes in reply to #14 5mo

Read the full topic (45 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. I have spent a fortnight trying to pin open-label extensions down…
PQZILUCMB 4 22k 3mo
[2026 update] Composite endpoints and the component doing the work
On the subject in the title: Composite endpoints and the component doing the work Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-4 ( Lancet , 2021) and…
CRSFDVFJP+76 87 994 3mo
Trial registration and comparing the protocol with the paper
Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin trial registration down and I want to…
AIRDRVOVAV+38 44 4.8k 10mo
Follow-up: Open-label extensions: what survives and what does not
Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin Open-label extensions down and I want to set…
MATPBLCMA+22 26 397 16mo
What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. Statistical analysis plan, and specifically the version…
AAZLHE 2 6.6k 10h

Related topics — sharing the tags estimand, intention to treat, open label

TopicParticipantsRepliesViewsActivity
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question
Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…
DPSGRIEDMB+80 91 10k 11mo
What TRIUMPH is designed to answer, and why we should not pre-empt it
What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. TRIUMPH keeps being re-asked here and I think…
NNRNCIHBEK+4 8 142 6h
Hepatic effects of glucagon receptor agonism: the mechanistic worry
Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Something about hepatic effects of glucagon receptor…
TOIOOID+51 56 700 22mo
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold?
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. A narrow question about semaglutide…
BDBEMVD 3 28k 6mo
Trial registration and comparing the protocol with the paper
Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin trial registration down and I want to…
AIRDRVOVAV+38 44 4.8k 10mo